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Background: Monocytes represent a heterogeneous population of cells subdivided according to the expression
level of membrane antigens. A pro-inflammatory (intermediate/nonclassical) subpopulation of monocytes is defined
by expression of CD16. CD163 seems to be characteristically preferentially expressed by immunosuppressive
monocytes. The aim of our study was to evaluate the distribution of monocyte subpopulations in 71 patients with
kidney allograft transplantation.
Results: The phenotype was evaluated by flow cytometry in defined time points. The proportions of peripheral
CD14+CD16+ monocytes were downregulated immediately after the kidney transplantation and basiliximab
treatment partially attenuated this trend. The transient downregulation of the CD14+CD16+ subpopulation was
adjusted to basal values in two months. The proportions of CD14+CD163+ monocytes were transiently
upregulated early after the kidney transplantation and remained higher during the first month in most patients. In
ATG treated patients, the expansion of CD14+CD163+ monocytes was delayed but their upregulation lasted
longer. In vitro data showed the direct effect of ATG and methylprednisolone on expression of CD16 and CD163
molecules while basiliximab did not affect the phenotype of cultured monocytes.
Conclusions: We assume from our data that kidney allograft transplantation is associated with modulation of
monocyte subpopulations (CD14+CD16+ and CD14+CD163+) partially affected by an immunosuppressive
regime used.
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In kidney transplantation, monocytic infiltration of the
graft plays a key role in renal dysfunction [1] and their
cytokines are actively involved in the process of acute re-
jection [2]. Peripheral blood monocytes represent highly
efficient effector cells of innate immunity subdivided
into different subpopulations by the expression level of
membrane antigens CD14 (a receptor for bacterial LPS)
and CD16 (Fc gamma RIII). These classical monocytes
are characterized by a very high expression of CD14 and
the absence of CD16 on their surface. Nevertheless, a
subpopulation of monocytes does exist with lower CD14
expression and detectable CD16 molecule on a mem-
brane [3]. These CD14+CD16+ intermediate/nonclassi-
cal monocytes represent up to 15% of peripheral blood* Correspondence: alena.sekerkova@ikem.cz
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reproduction in any medium, provided the ormonocytes but their numbers may be increased in pa-
tients with bacterial sepsis, TB or HIV infections [4].
These monocytes are smaller [5] and can be distin-
guished from CD14+CD16- monocytes by high HLA-DR
and CD43 expression [6]. The subpopulations of mono-
cytes also differ in the expression of chemokine receptors
[7] and some of the functional activities. CD14+CD16+
monocytes are high producers of proinflammatory cyto-
kine TNF alpha with limited capability to release anti-
inflammatory IL-10 [8]. High expression of HLA-DR anti-
gens might be one of the factors responsible for better
antigen-presenting capacity of CD14+CD16+ monocytes
[9]. In consideration of these properties, CD14+CD16+
cells should be considered as characteristic intermediate/
nonclassical proinflammatory monocytes. The proportion
of this monocytic subpopulation in the peripheral blood
may be increased also in non-infectious inflammatory dis-
orders such as Crohn’s disease [10], rheumatoid arthritis
[11], bronchial asthma or sarcoidosis [12]. Furthermore,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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spect to the pathophysiology of atherosclerosis [13,14] in-
cluding kidney transplant patients [15]. In contrast to
these intermediate/nonclassical CD14+CD16+ monocytes,
CD163 expression seems to be a marker of monocyte sub-
set downregulating immune responses. This scavenger
molecule for hemoglobin-haptoglobin complexes [16]
functions also as a receptor for cytokine TWEAK [17] and
some bacteria [18] and its expression is upregulated in re-
sponse to glucocorticoids [19]. CD163 positive monocytes
and macrophages (designed as M2 subset) are known to
produce cytokine IL-10 suppressing effector immune
mechanisms [20]. Among other myeloid antigens, the
CD36 known to be upregulated during monocyte extrava-
sation [21], and CD74, a receptor for macrophage migra-
tion inhibitory factor [22], represent additional markers of
potential interest. In this respect, the aim of our prospect-
ive observational study was to monitore changes of per-
ipheral monocyte subpopulations in early phases of kidney




In total, 20 healthy control and 71 patients who under-
went renal transplantation from a deceased donor were
enrolled in the study. Healthy controls were volunteers
(age between 25–50 years) with no clinical symptoms,
with no significant clinical diagnosis. None of the en-
rolled volunteers had transplantation in the past.
All patients were treated by a triple maintenance ther-
apy consisting of calcineurin inhibitor (CNI, either ta-
crolimus or cyclosporine A), mycophenolate mofetil
(MMF) and corticosteroids, with or without induction
therapy. MMF and steroid therapy was started at day 0,
CNI was given at day 0 or 1 of transplantation. Patients
with panel reactive antibodies (PRA) >50% received 1–
1.5 g/kg/day of rATG (ThymoglobulinW, Genzyme Cor-
poration, Cambridge, MA, USA; n = 28) in 2 to 7 doses
during the first postoperative week with respect to de-
pletive effect. Patients with PRA 20-50% or those who
received a kidney from extended criteria donor were
treated by 20 mg of basiliximab (SimulectW, Novartis, Basel,
Switzerland n = 18) on days 0 and 4. Low risk patients
(PRA <20%) received no induction therapy (control group,
n = 25).
Except for a difference in the frequency of retransplan-
tation, mean percentage of panel reactive antibodies
(PRA), and donor age, the clinical characteristics did not
differ significantly between the three groups (Table 1).
Peripheral blood samples were collected at following
time-points: before transplantation and 7, 14, 21, 28, 60,
90 days and 6, 12 months post-transplantation. Serum
creatinine (SCr), incidence of delayed graft function(DGF), estimated glomerular filtration rate (eGFR, calcu-
lated using MDRD1 formula), proteinuria and incidence
of rejection during 3 months after transplantation and at
3-month protocol biopsy were recorded in patients. All
patients gave their informed consent and signed their
agreement with each biopsy performed. The study proto-
col was approved by the Ethics Committee of the Institute
for Clinical and Experimental Medicine (No.:608-08-10).
All patients underwent renal graft biopsy upon clinical
presumption of acute rejection such as insufficient de-
cline or sudden rise of serum creatinine. Furthermore,
patients underwent the protocol biopsy at three months
after transplantation. Biopsy-proven acute rejection was
diagnosed histologically according to the Banff ’05 clas-
sification [23]. Borderline changes and T cell-mediated
rejection (TCMR) grade I and IIA were treated by 1.5-
2 g of methylprednisolone, TCMR grades IIB, III and
steroid-resistant TCMR by rATG (10 dose; 2 mg/kg 1st
day and 1 mg/kg 2nd-10th day of treatment) and
antibody-mediated rejection (AMR) by plasma exchange
and intravenous immunuglobulin alternately during
10 days.
Three patients with no induction who obtained rATG
as a treatment of severe acute rejection (first dose: day
12, 8 and 8) were excluded from group comparison sta-
tistics of flow cytometry data.
Flow cytometry
Peripheral blood mononuclear cells (100 ul, approx.
1*106) were labeled with fluorochrome-conjugated (PE –
phycoerythrin, PC7 – phycoerythrin-cyanine 7, PC5 –
phycoerythrin-cyanine 5, FITC – fluorescein) monoclonal
antibodies resuspended in PBS-BSA buffer for 20′ at room
temperature (RT) in the dark. The following antibodies
were used: CD36-FITC, CD14-PC7, CD16-ECD (Beckman
Coulter, Brea, CA, USA), CD74-Alexa Fluor 647, CD163
(clone GHI61)-PE, CD163 (clone RM3/1)-PE (BioLegend).
Fresh blood (100 ul) with monoclonal antibodies were
incubated 20′ in the room temperature in the dark. Sam-
ples were lysed with 0.5 ml lysing solution OptilyseC
(Beckman Coulter, Brea, CA, USA) 10′ the room tem-
perature in the dark. Lysing reaction was stoped with 1 ml
CellWash (optimized PBS) (Beckton Dickinson Bio-
science, Benelux, Belgium). Samples were measured on a
FC 500 flow cytometer (Beckman Coulter, Brea, CA,
USA) and analyzed using CxP software and Kaluza soft-
ware (Beckman Coulter, Brea, CA, USA). Gating strategy:
monocytes were gated by side scatter and CD14 expres-
sion. Subsequently CD 16, CD36, CD74 and CD163 were
measured on the cell surfaces. A flow cytometry analysis
was performed with at least 100 events in the gate. The
absolute number of monocyte subpopulations are calcu-
lated from the absolute number of leukocytes and are
shown as number of cells * 106/l. Absolute number of
Table 1 Demographic characteristics at the time of transplantation
No induction rATG Basiliximab P-value
Number 25 28 18
Gender (male/female) 14/11 19/9 9/9 n.s.b
Recipient age (years) 57,9 [27.7; 73.3] 52,9 [21.5; 78.6] 52,9 [25.6; 67.1] n.s.d
Donor age (years) 52.0 [16.0; 68.0] 46.5 [22.0; 74.0] 63.5 [46.0; 75.0] <0.001d,e
aHLA MM 3 [1; 6] [2; 5] [1; 5] n.s.d
1st/2nd and 3rd T x R (n) 25/0 12/16 18/0 <0.0001b
aPRA (%) 4 [0; 36] 64 [0; 96] 7 [0; 44] <0.0001d,g
aCNI (TAC/CsA)(n) 21/4 28/0 18/0 n.s.b
aCIT (hours) 15.2 [11.0; 20.7] 15.9 [7.7; 22.8] 17.6 [12.4; 21.0] n.s.d
Dialysis time (years) 2.0 [0.2; 9.42] 2.2 [0.5; 6.37] 2.1 [0; 4.9] n.s.d
Cause of renal failure n.s.
Primary GN 10 10 5
Hereditary diseases 4 6 6
Diabetic or ischaemic nephropathy 8 2 5
aTIN 2 3 1
aANCA vasculitis or lupus nephritis 0 4 0
Other causes 1 3 1
aANCA, anti-neutrophil cytoplasmic antibodies; CIT, cold ischaemic time; CNI, calcineurin inhibitor; CsA, cyclosporine A; GN, glomerulonephritis; HLA MM, HLA
mismatch; PRA, historical panel reactive antibodies, measured every 3 months before transplantation, the highest number was considered in each patient; TAC,
tacrolimus; TIN, tubulointerstitial nephritis; T 3, renal transplantation.
bChi square test P-value.
dKruskal–Wallis test P value.
eDunn’s multiple comparison test: significant difference between the basiliximab group and the rATG or controls.
gDunn’s multiple comparison test: significantp difference between rATG and the no induction or basiliximab groups.
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(Sysmex Corporation, Japan).
“In vitro” cultures of peripheral blood mononuclear
cells ( PBMCs)
Three healthy volunteers (between 30–55 years) with no
clinical symptoms, with no significant clinical diagnosis
and without transplantation in the past were selected for
in vitro experiments. Fresh blood (50 ml) was collected
from each individual into a tube containing EDTA.
PBMCs were purified using standard Ficoll-Paque gradi-
ent centrifugation. Briefly, 3 ml of Ficoll-Paque gradient
was pipetted into a 15-ml centrifuge tube. The EDTA
blood was diluted 1:1 in phosphate-buffered saline (PBS)
and carefully layered over the Ficoll-Paque gradient (3 ml/
tube). The tubes were centrifuged for 30 min at 580 × g.
The cell interface layer was harvested carefully and the
cells were washed once in PBS (for 10 min at 180 × g) and
then once in RPMI-1640 medium (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 10% heat inactivated
fetal calf serum (FCS), L-glutamin, penicillin and strepto-
mycin (Sigma-Aldrich), (for 10 min at 180 × g). Cells were
harvested from the surface by using Trypsin-EDTA
(Sigma-Aldrich, St. Louis, MO, USA).
Isolated cells were cultured in duplicates in 24-well tis-
sue culture plates (Costar, Corning, NY, USA) under a 5%CO2 atmosphere at 37° in RPMI-1640 supplemented
with ATG (1, 10 and 100 ug/ml), basiliximab (1, 10,
100 and 1000 ng/ml) or methylprednisolon (10, 100,
1000 ug/ml). Non-stimulated cells were used as a nega-
tive control. The proportions of CD14+CD16+ and
CD14+CD163+ monocytes were evaluated in dupli-
cates by flow cytometry at times 0;1;3;6;24;48 and
72 hours after stimulation. Cell viability was evaluated
using a Vi-Cell analyzer (Beckman Coulter, Brea, CA,
USA). In ATG-stimulated cells, 72 h culture affected
the viability of monocytes and data were not analyzed
at this time point.
Statistics
Statistical analyses were performed by GraphPad Prism 5
software (GraphPad Software, La Jolla, CA, USA) and
BMDP PC-90 statistical software (BMDP Statistical Soft-
ware Inc., Los Angeles, CA, USA). Based on the distribu-
tion of the data (Shapiro-Wilk’s test for normality), we
performed parametric or nonparametric (Mann–Whitney,
Kruskal-Wallis) testing. For analysis of categorical va-
riables, the chi-square test was used. Data are showed as
median [min; max] according to the distribution. Ana-
lysis of data from flow cytometry was performed by
ANOVA with repeated measures, comparison within
groups between two time points by contrasts. Dynamics
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the estimated coefficients were compared by z-statistcs.
Results
Patient and graft survival
From a total of 71 patients, three patients underwent
graft nephrectomy (Day 4, 20 and 58 after transplant-
ation) for renal vein thrombosis, acute hemorrhage after
biopsy or primary non-functional graft, respectively; 2
patients died on Days 56 and 80 of sudden death and
pulmonal artery embolism, respectively. Two patients
withdrew their informed consent to participate in the
study at Days 14 and 60.
Graft function
The three patient groups examined did not differ in the
incidence rates of DGF: controls: 8/25 (32%); the rATG
group: 7/28 (25%) and the basiliximab group: 9/18 (50%).
No significant differences in the levels of SCr, eGFR and
proteinuria were observed, respectively, between treat-
ment groups 90 days post-transplantation: controls, 127
[61; 314] μmol/L, 0.76 [0.19; 1.46] mL/s/1.73 m2 and 0.22
[0.07; 2.18] g/24 h; rATG, 120 [57; 239] μmol/L, 0.78
[0.29; 1.57] mL/s/1.73 m2 and 0.18 [0.10; 2.15] g/24 h and
basiliximab, 153 [79; 278] μmol/L, 0.59 [0.28; 1.10] mL/s/
1.73 m2 and 0.28 [0.07; 0.49] g/24 h.
Graft rejection
Acute rejection occurred during the first 3 months in
4/24 (16.7%) control group patients, 3/28 (10.7%) rATG
patients and in 2/18 (11.1%) basiliximab-treated pa-
tients (P > 0.05). There were another five patients with
borderline changes in the control group and seven were
treated with basiliximab. In patients without induction
therapy, two patients suffered from early acute TCMR,
one patient from acute AMR and one patient had a
combined type of rejection. In patients with rATG in-
duction, three patients suffered from AMR and in those
with basiliximab, one patient suffered from early acute
TCMR and one from combined acute TCMR and AMR.
Peripheral blood CD14+CD16+ monocytes after kidney
allograft transplantation
The percentage of peripheral CD14+CD16+ monocytes
was found to be downregulated during 7 days after the
kidney transplantation in the group of patients without
the induction therapy (p < 0.0005) and those treated with
thymoglobulin (p < 0.0002). In patients treated with anti-
CD25 antibody basiliximab, the decrease in percentage
of CD14+CD16+ reached the minimum after two weeks
and the moderate changes did not reach statistical signifi-
cance (p = ns) (Figures 1 and 2). In most patients, the
transient downregulation of CD14+CD16+ subpopulationwas almost adjusted in three months but did not reach
the values obtained before the transplantation.
Peripheral blood CD14+CD163+ monocytes after kidney
allograft transplantation
The percentage of peripheral CD14+CD163+ monocytes
was found to be upregulated during 7 days after the
kidney transplantation in the group of patients without
the induction therapy (p < 0.0001) and those treated
with basiliximab (p < 0.0001). In patients treated with
thymoglobulin, the upregulation in percentage of
CD14+CD163+ reach the maximum after two weeks
(p < 0.001) (Figures 3 and 4). In most patients, the upregu-
lation of CD14+CD163+ subpopulation was almost ad-
justed in three or six months but did not reach the values
obtained before the transplantation. In the pooled group of
kidney transplant recipients (n = 71), marked upregulation
of CD14+CD163 subpopulation is in contrast with minimal
changes in whole monocyte population (Figure 5).
Peripheral blood CD14+CD16+ and CD14+CD163+
monocytes in patients with acute rejection of
kidney allograft
Our preliminary data obtained from two patients under-
going acute rejection showed the trend to upregulation
of CD14+CD16+ monocytes in these subjects as demon-
strated in a case report of two study subjects (Figure 6).
“In vitro” effect of immunosuppressives on phenotype of
human monocytes
In order to assess the direct effect of immunosuppres-
sives, the proportions of monocyte subpopulations
CD14+CD16+ and CD14+CD163+ were evaluated in
cultured PBMC exposed to rATG, basiliximab, and
methylprednisolone. Exposition of PBMC to rATG
(Figure 7a) reduced the percentage of CD14+CD16+
monocytes in 1 hour and the decline continued until
48 hours. In contrast, percentage of CD14+CD16+
monocytes in control samples gradually grew up to
75% from initial 10% of cells (p < 0.05). The data sug-
gest that rATG is effective already at very low con-
centrations. In contrast, basiliximab does not affect
the proportions of CD14+CD16+ monocytes at all
(Figure 7b). Methylprednisolone (Figure 7c) upregu-
lated the percentage of CD14+CD16+ monocytes after
48 hours (p < 0.05) compared to the control.
Monocytes incubated with rATG (Figure 8a) upregu-
lated the expression of CD163+ after 6 hours and the
proportion of CD14+CD163+ monocytes increased from
6% at the time point 0 h to 50% at the time point 48 h
(p < 0.01) . In control cultures of PBMCs, the percentage
of CD14+CD163+ monocytes reach the maximum of
20% after 48 hours (p < 0.05). Basiliximab at the all con-









































































































a b c 
Figure 1 Percentage of peripheral blood CD14+CD16+ monocytes after kidney allograft transplantation. The co-expression of CD14 and
CD16 antigens on peripheral blood monocytes was evaluated by flow cytometry in three different groups of patients undergoing kidney allograft
transplantation (a-without induction, b-thymoglobulin, c-basiliximab). In patients without the induction therapy (n = 25 ) and those treated with
thymoglobulin (n = 28 ), the percentage of CD14+CD16+ monocytes decreased during the first two weeks after the transplantation as compared
to only moderate changes observed in subjects treated with basiliximab (n = 18). Analysis of data from flow cytometry was performed by ANOVA
with repeated measures and a comparison within groups between two time points by contrasts. *Statistically significant differences.
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Methylprednisolon (10 and 100 μg) has been shown to
be the strongest inducer of CD14+CD163+ monocytes
and upregulated their proportions from 6% to 90% in
the first 6 hours (p < 0.05) (Figure 8c). Concentrations
higher than 1000 ug/ml were found to be toxic, the re-
sults of cell viability tests are shown in the Table 2.
Peripheral blood monocyte expression of CD36 and CD74
after kidney allograft transplantation
Constitutive CD36 expression was found in more than
98% of monocytes without any dynamic changes du-
ring the post-transplantation period. Similarly, a high
density CD74 expression was present in all peripheral
blood monocytes without any changes. Proportions of
peripheral blood monocytes in the frame of wholeFigure 2 Downregulation of CD14+CD16+ monocyte subpopulation a
the data of one representative patient without the induction therapy. The
week after the kidney transplantation.blood count were not affected during the 12 months
period after the kidney allograft transplantation (not
shown).
Discussion
Our data suggest that kidney allograft transplantation is as-
sociated with evident shifts in proportions of specific mono-
cyte subpopulations CD14+CD16+ and CD14+CD163+ and
these changes are partially affected by the immunosuppres-
sive regime used. During the first week after the trans-
plantation, the proportion of intermediate/nonclassical
CD14+CD16+ monocytes is downregulated which might
be due to their trafficking to the graft or by their selective
deletion. Obviously, no bioptical data to prove the presence
of CD14+CD16 monocytes in the graft immediately
after the surgery were obtainable from ethical reasons.fter the kidney transplantation. The flow cytometry plot expresses









































































































a b c 
Figure 3 Percentage of peripheral blood CD14+CD163+ monocytes after kidney allograft transplantation. The presence of CD14+
CD163+ monocytes in peripheral blood was evaluated by flow cytometry during the first year after the kidney allograft transplantation. In
patients without the induction therapy a (n = 25 ) and those treated with basiliximab c (n = 18 ), the percentage of CD14+CD163+ monocytes
dramatically increased during the first week after the transplantation in contrast to subjects treated with thymoglobuline b (n = 24). Analysis of
data from flow cytometry was performed by ANOVA with repeated measures and a comparison within groups between two time points by
contrasts. *Statistically significant differences.
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cytes seems to us more relevant since recent data showing
that these monocytes are senescent [24] also indirectly
suggest that they might be more sensitive to the aggressive
environment of a “cytokine storm” associated with the is-
chemia/reperfusion injury. The initial values of CD14
+CD16+ monocytes before the kidney transplantation
were higher as compared to values in healthy subjects
reflecting the end stage kidney disease [14].
The effect of different treatment regimes was also
observed. A statistically significant decrease of the
CD14+CD16+ monocytes in the first week after trans-
plantation was observed in patients without induction
therapy and those treated with rATG. Patients treated
with basiliximab achieved only moderate decrease afterFigure 4 Expansion of CD14+CD163+ monocytes following kidney tra
patient with basiliximab induction therapy. The percentage of CD14+CD16
the transplantation.two weeks of treatment. In this respect, we also dem-
onstrated the direct effect of rATG on the decrease of
CD14+CD16+ monocytes in cultured PBMCs while
basiliximab did not affect this monocytic subpopu-
lation “in vitro”. The reason for the different cellular
response may be due to different mechanism of action
of rATG and basiliximab. Polyclonal rATG leads to
an immediate targeted depletion of T lymphocytes
together with evident effects on other immune cells
while basiliximab binds to the α-chain of IL-2R (CD25)
on the T lymphocyte surface, so that T lymphocytes
are not able to bind to IL-2. This treatment affects
mainly IL-2 and T lymphocyte mediated immune re-
sponses and probably does not directly affect mono-
cytes [25].nsplantation. The flow cytometry plot expresses the data of one
3+ monocytes was highly upregulated during the first week after
Figure 5 Proportional changes of CD14+CD163+ subpopulation as compared to the whole population of peripheral blood monocytes.
The absolute numbers of peripheral blood monocytes and their CD14+CD163 subpopulation were monitored during the first year following
kidney allograft transplantation (n = 71). The early massive upregulation of CD14+CD163+ subpopulation is in a contrast with only moderate
changes observed in whole population of peripheral blood monocytes (absolute numbers of monocyte subpopulations are calculated from the
total number of leukocytes and are expressed as number of cells *106/l).
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sult of prednisolone treatment as a part of standard im-
munosuppressive regimes since in vitro, the induction of
this molecule on monocytes by glucocorticoids has been
already documented [19] and our data confirmed early
induction of CD163 expression on monocytes in responseFigure 6 Case reports of two patients with complicated outcome of kidn
subpopulation. Patient No.1 is a 56-year old male with delayed graft func
kidney allograft transplantation, treated successfully with thymoglobulin. Pa
(FACSXM positive, presence of MICA antibodies) diagnosed one month
and subsequent IVIG therapy, the kidney functions became stable. In b
of CD14+CD16+ monocytes. TCMR= T cell-mediated rejection, ATN = acute t
calculated from the total number of leukocytes and are expressed as numberto methylprednisolone. In addition to increasing the num-
ber of monocytes expressing CD163, methylprednisolone
also upregulated the density CD163 on the cells surface.
Surprisingly, the delayed effect of CD163 induction in
thymoglobulin-treated patients was associated with its
prolonged expression and might be regulated by otherey allograft transplantation associated with changes of CD14+CD16+
tion and diagnosed acute cellular rejection IIB in early phase following
tient N. 2 is a 51-year old male with C4d negative humoral rejection
after the transplantation. After changing of immunosuppression
oth cases, the clinical status of patients correlated with proportions
ubular necrosis (absolute numbers of monocyte subpopulations are
of cells *106/l).
































































a b c 
Figure 7 In vitro effect of immunosuppressives on the percentage of CD14+CD16+ monocytes peripheral blood monocytes collected
from a healthy donor were cultured in the presence of rATG, basiliximab and methylprednisolone. Changes of CD16 expression on the
surface CD14-positive monocytes were measured at following time points: 0, 1, 3, 6, 24, 48 and 72 h. Incubation with rATG (a) downregulated the
proportion of CD14+CD16+ monocytes already after one hour. Basiliximab (b) had no effect. Methylprednisolone (c) upregulated the percentage
of CD14+CD16+ subpopulation. Dynamics of the parameters was fitted by quadratic regression and the estimated coefficients were compared
by z-statistcs.
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http://www.biomedcentral.com/1471-2172/15/4induced cells since it lasted for 3 months after the last
treatment with this polyclonal antibody. The initial pro-
portions of CD14+CD163+ monocytes did not differ
from values of healthy subjects.
Simultaneously “in vivo”, we found a decreased num-
ber of total peripheral blood monocytes one week after
transplantation in the patients group receiving rATG.
The ability of rATG to induce apoptosis of monocytes
has been demonstrated. It is assumed that monocyte de-
pletion by rATG might contribute to the prevention of
GVHD [26]. rATG effect on the monocytes function, in-
cluding the expression of surfaces markers and produc-














































Figure 8 In vitro effect of immunosuppressives on the percentage of
from a healthy donor were cultured in the presence of rATG, basilixim
cultured monocytes was measured at following time points: 0, 1, 3, 6, 24, 48 a
proportion of CD14+CD163+ monocytes while basiliximab (c) had no effect.
estimated coefficients were compared by z-statistcs.Furthermore, we have analyzed a potential relationship
between the proportion of monocyte subpopulations and
PRA values and have not found any correlations (data not
shown). In few patients undergoing acute rejection of kid-
ney allograft, the intermediate/nonclassical CD14+CD16+
monocytes are upregulated and their capacity to release cy-
tokines like TNF alpha and IL-1 beta might be indirectly
involved in downregulation of the CD14+CD163+ pheno-
type. In human monocytes, CD163 expression is known to
be downregulated in vitro by IFN gamma [27], a cytokine
associated with Th1 mediated rejection mechanisms. Our




























CD14+CD163+ monocytes peripheral blood monocytes collected
ab and methylprednisolone. Membrane expression of CD163 on
nd 72 h. Both the rATG (a) and methylprednisolone (b) upregulated the
Dynamics of the parameters was fitted by quadratic regression and the
Table 2 Viability of the cells (“in vitro” experiments)
rATG
Hour Control 1 µg/ml 10 µg/ml 100 µg/ml
0 94,1 ± 1,0 96,1 ± 1,3 96,3 ± 1,8 95,1 ± 2,2
24 97,4 ± 1,8 95,9 ± 1,8 94,2 ± 3,2 93,2 ± 1,9
48 93,2 ± 2,6 94,6 ± 2,1 95,6 ± 1,9 92,7 ± 1,3
72 97,3 ± 1,4 96,1 ± 2,5 94,8 ± 2,1 95,2 ± 1,2
Basiliximab
Hour Control 1 ng/ml 10 ng/ml 100 ng/ml 1000 ng/ml
0 96,1 ± 1,1 95,8 ± 1,9 95,3 ± 1,6 93,6 ± 0,8 93,5 ± 1,8
24 97,3 ± 2,1 92,1 ± 2,1 96,2 ± 1,1 94,6 ± 1,2 93,8 ± 2,5
48 97,2 ± 1,8 96,4 ± 2,2 98,1 ± 0,5 93,8 ± 2,1 95,1 ± 1,8
72 96,3 ± 2,4 93,9 ± 1,9 95,6 ± 2,1 94,3 ± 3,1 96,2 ± 1,3
Methylprednisolone
Hour Control 10 µg/ml 100 µg/ml 1000 µg/ml
0 95,1 ± 1,3 95,1 ± 1,2 96,9 ± 2,1 84,2 ± 3,8
24 96,9 ± 2,5 95,8 ± 1,8 96,9 ± 1,8 33,4 ± 8,9
48 96,7 ± 1,3 96,2 ± 2,2 95,1 ± 2,1 38,1 ± 10,3
72 95,6 ± 2,1 97,0 ± 1,9 95,3 ± 2,3 31,1 ± 10,2
Viability of the cells was measured on the bases of penetration of trypan blue into the cells.
Sekerkova et al. BMC Immunology 2014, 15:4 Page 9 of 10
http://www.biomedcentral.com/1471-2172/15/4With respect to standardization procedures, our experi-
ments confirmed the differences in domain specific bin-
ding of anti-CD163 antibodies which are responsible for
published discrepancies in CD163 monocyte positivities
[28]. We tested two different clones (RM3/1 and GHI61)
for the detection of CD163 but only GHI61 clone bound
to the surface of blood monocytes in contrast to the epi-
tope recognized by clone RM3/1 expressed exclusively on
the surface of macrophages and completely absent in
monocytes (data not shown).Conclusions
Both the initial phase of kidney transplantation immediately
after the graft reperfusion and acute rejection process
are associated with multiple immunological reactions
and changes in the proportions of monocyte subpopula-
tions might be one of the key factors. Estimating the
number of peripheral intermediate CD14+CD16+ and
“anti-inflammatory” CD14+CD163+ monocytes might
be one of new potentially perspective laboratory pa-
rameters to evaluate immune responses in kidney
transplant recipients. The induction of immunosup-
pressive CD14+CD163+ monocytes and downregula-
tion of proinflammatory intermediate/nonclassical
CD14+CD16+ monocytes might play a protective role
in the early phase after kidney transplantation. On the
other hand, we have not performed any functional tests
to confirm immunosuppressive or proinflammatory
properties of these cells in this study.Abbreviations
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